[Infections in patients with gynecologic malignancies].
Infections in patients with gynecologic malignancies occur frequently and are the cause of death in 50 to 60% of the cases. The patient with cancer is a compromised host with an increased susceptibility to infection due to the malignancy itself on the one hand and due to therapeutic-modalities, like extensive surgical procedures, radiation- and cytotoxic chemotherapy on the other hand. Aetiologically these infections are mostly due to a disruption of anatomic structures which normally prevent the invasion of exogenous or endogenous microorganisms, or to obstructive processes or to tumour necrosis. Septicaemia can result from propagation of such a localized infection beyond the site of the tumour. The causative pathogens infecting the compromised host are mostly members of the indigenous microbial flora of the genital tract, which is influenced by surgery, irradiation and chemotherapy. Postoperatively in the vaginal vault the number of most potentially pathogenic aerobic and anaerobic bacterial species is higher, polymicrobial mixed infections are frequent. Neither the intracavitary radiation-therapy with Radium or Iridium-192 (afterloading) nor the external high-voltage therapy decrease the number of pathogenic bacterial species in the uterus and in the vagina of patients with cervical or endometrial cancer. The symptoms of infection in cancer patients can be "masked". Fever in patients with genital malignancies is mostly due to local infections and influences the prognosis negatively. The 5-year survival rate of irradiated patients with fever is significantly lower. Infections following radical hysterectomy, irradiation and/or cytotoxic chemotherapy like pelvic abscesses, peritonitis, pneumonia and septicaemia can be fatal. Urinary-tract-, wound- and vaginal vault-infections occur frequently, but are rarely severe. Therapeutically in severe infections a combination antibiotic therapy, which is effective against most pathogenic members of the genital flora, is required. Short courses of perioperative prophylactic antibiotics are useful both in radical hysterectomy and with intracavitary irradiation.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000009:adverse effects; D001420:Bacteria, Aerobic / Q000472:pathogenicity; D001421:Bacteria, Anaerobic / Q000472:pathogenicity; D001424:Bacterial Infections / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy; D008212:Lymphocyte Depletion; D008264:Macrophages / Q000276:immunology; D011502:Protein-Energy Malnutrition / Q000209:etiology
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents
Infektionen bei Patientinnen mit gynäkologischen Malignomen.